The Commission, furthermore, due to a lack of a clearly defined entrustment act for each exemption rejected the argument that the measure could be regarded as a measure of general economic interest but rather considered it to constitute a selective advantage in favour of certain pharmaceutical companies active in the production of certain goods.
32 3. DESCRIPTION OF THE MEASURE › 3.3. Grounds for initiating the procedure, Decision_act (EU) 2015/1300
In forcesince 27 Mar 2015